Abstract
We report a case of severe thrombocytopenia following pegylated interferon-alpha 2a (Peg-IFN-alpha 2a) treatment of hepatitis C virus infection and summarize the clinical characteristics of 16 cases of IFN-alpha induced severe thrombocytopenia and its immune-mediated mechanism. Discontinuation of IFN-alpha and early administration of immunosuppressants are the effective therapy for IFN-alpha induced severe thrombocytopenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
